Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS).

Autor:	Neuzillet C; Department of Medical Oncology, Curie Institute, Versailles Saint-Quentin University (UVSQ) - Paris Saclay University, Saint-Cloud, France cindy.neuzillet@gmail.com., Anota A; Methodology and Quality of Life Unit in Oncology, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University Hospital of Besançon, University Bourgogne Franche-Comté, Inserm, EFS BFC, Besançon, France.; Biostatistics Unit, DRCI, Centre Léon Bérard, Lyon, France., Foucaut AM; Laboratoire Educations et Pratiques de Santé UR 3412, Université Sorbonne Paris Nord, Bobigny, France., Védie AL; Department of Gastroenterology and Pancreatology, Beaujon University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris 7 Diderot University, Clichy La Garenne, France., Antoun S; Nutrition and Readaptation Unit, Gustave Roussy Institute - Cancer Campus, Villejuif and Chevilly-Larue, France., Barnoud D; Department of Intensive Clinical Nutrition, Hospices Civils de Lyon (CHU Lyon), Lyon, France., Bouleuc C; Department of Supportive Care, Curie Institute, Paris, France., Chorin F; Plateforme Fragilité, Université Côte d'Azur, CHU Nice, LAMHESS, Nice, France., Cottet V; INSERM UMR1231 CIC 1432, CHU Dijon, NACRe National Network, University of Burgundy Franche-Comté, Dijon, France., Fontaine E; University of Grenoble Alpes, INSERM, LBFA, Grenoble, France., Garabige V; Department of Supportive Care, Curie Institute, Paris, France., Hébuterne X; Gastroenterology and Clinical Nutrition, CHU of Nice and University Côte d'Azur, Nice, France., Huguet F; Service d'Oncologie Radiothérapie, CHU Tenon, IUC, AP-HP, Sorbonne Université, Paris, France., Lièvre A; Department of Gastroenterology, INSERM U1242 'Chemistry Oncogenesis Stress Signaling', University Hospital Pontchaillou, Rennes 1 University, Rennes, France., Marchal T; Department of Supportive Care, Curie Institute, Paris, France., Mouillot T; Service d'Hépato-gastro-entérologie, CHU F. Mitterrand, Dijon, France., Peschaud F; Department of Surgical Oncology, CHU Ambroise Paré, APHP, UVSQ - Paris Saclay University, Boulogne-Billancourt, France., Quilliot D; Nutritional Assistance Department and Transversal Nutrition Unit, University Hospital of Nancy, University of Lorraine, Nancy, France., Raynard B; Nutrition and Readaptation Unit, Gustave Roussy Institute - Cancer Campus, Villejuif and Chevilly-Larue, France., Schneider S; Plateforme Fragilité, Université Côte d'Azur, CHU Nice, LAMHESS, Nice, France., Scotté F; Department of Supportive Care (Département Interdisciplinaire d'Organisation des Parcours Patients - DIOPP), Gustave Roussy Institute - Cancer Campus, Villejuif, France., Vansteene D; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France., Mariani P; Department of Digestive Surgery, Curie Institute, Paris, France., Bouché O; Department of Digestive Oncology, CHU Reims, Reims, France., Joly F; Department of Gastroenterology, IBD and Nutrition Support, CHU Beaujon, AP-HP, Paris 7 Diderot University, Clichy La Garenne, France.
Jazyk:	angličtina
Zdroj:	BMJ supportive & palliative care [BMJ Support Palliat Care] 2021 Dec; Vol. 11 (4), pp. 381-395. Date of Electronic Publication: 2020 Nov 11.
DOI:	10.1136/bmjspcare-2020-002751
Abstrakt:	This document is a summary of the French intergroup guidelines regarding the nutrition and physical activity (PA) management in digestive oncology. This collaborative work was produced under the auspices of all French medical and surgical societies involved in digestive oncology, nutrition and supportive care. It is based on published guidelines, recent literature review and expert opinions. Recommendations are graded according to the level of evidence. Malnutrition affects more than half of patients with digestive cancers and is often underdiagnosed. It has multiple negative consequences on survival, quality of life and risk of treatment complications. Consequently, in addition to anticancer treatments, supportive care including nutritional support and PA plays a central role in the management of digestive cancers. It is crucial to detect malnutrition (diagnostic criteria updated in 2019) early, to prevent it and to act against it at all stages of the cancer and at all times of the care pathway. In this context, we proposed recommendations for the evaluation and management in nutrition and PA in digestive oncology for each stage of the disease (perioperative setting, during radiation therapy, during systemic treatments, at the palliative phase, after cancer). Guidelines for nutrition and PA management aim at increasing awareness about malnutrition in oncology. They are continuously evolving and need to be regularly updated. Competing Interests: Competing interests: CN: Consultancy/honoraria: Pierre Fabre, Servier, Roche, AstraZeneca, Bristol-Myers Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, Fresenius Kabi; Research funding: Roche; Clinical trials: OSE Immunotherapeutics, AstraZeneca, Bristol-Myers Squibb, Merus. A-MF: Pierre Fabre, Ceformed, MéthodCO. EF: Baxter, Nutricia, Fresenius Kabi, Aguettant, BBraun. XH: clinical research funding from AbbVie; Abivax; Alphasigma; Celgene; Gilead Science, Inc; Eli Lilly; Enterome, Janssen; InDex Pharmaceuticals; Pfizer; Roche; Salix; Takeda; Theravance; advisory boards for AbbVie, Arena Pharmaceuticals, Arkopharma, Astellas, Janssen, Nutricia, Pfizer, Sangano, Takeda; lectures and educational activities for AbbVie, Baxter, Bristol-Myers Squibb, Ferring, Janssen, MSD, Mylan, Nutricia, Pfizer, Sanofi-Advantis, Tillots and Takeda. AL: grants from Bayer Lilly, Merck and Novartis; personal fees from AAA, Amgen, Bayer, Bristol-Myers Squibb, Celgene, HalioDx, Incyte, Ipsen, Lilly, Merck, Novartis, Pierre Fabre, Roche, Sandoz, Sanofi and Servier; non-financial support from AAA, Amgen, Bayer, Incyte, Ipsen, Merck, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Servier and Integragen. TM: Baxter, Nutricia, Nestle. BR: honoraria from Fresenius Kabi for Scientific Board (NUTRICANCER2 and SCAN studies). SS: Baxter, B. Braun, Fresenius-Kabi, Laboratoires Grand-Fontaine, Nestlé Health Science and Nutricia. DV: Fresenius Kabi, Nutricia, Nestle Health Science. OB: Merck KGaA, Roche, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Servier and Pierre Fabre. (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu